Características clínicas y tratamiento de pacientes con Artritis reumatoide en el Hospital Distrital de Ñemby, Año 2024

Karen Aracely Rodríguez Torres; Julio César Palacios Coronel; Edgar Ortega Filártiga

doi:10.53732/rccsalud/2025.e7124

Authors

Karen Aracely Rodríguez Torres Universidad del Pacífico, Facultad de Ciencias Médicas. Asunción, Paraguay https://orcid.org/0009-0004-3943-0988
Julio César Palacios Coronel Universidad del Pacífico, Facultad de Ciencias Médicas. Asunción, Paraguay https://orcid.org/0009-0003-8540-0969
Edgar Ortega Filártiga 2Hospital Nacional de Itauguá, Departamento de Medicina Interna. Itauguá, Paraguay https://orcid.org/0000-0001-9129-3408

DOI:

https://doi.org/10.53732/rccsalud/2025.e7124

Keywords:

rheumatoid arthritis, rheumatoid factor, anti-ccp, treatment, Paraguay

Abstract

Introduction. Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that mostly affects women. Objective. To determine the clinical characteristics and treatment of patients with RA at the Ñemby District Hospital in 2024. Materials and Methods. An observational, descriptive, retrospective, cross-sectional study was conducted including 300 patients over 18 years of age diagnosed with RA according to the American College of Rheumatology criteria. Results. The mean age of the population was 51 years, with a predominance of females 78.67%. The most common type of joint involvement was oligoarticular in 72%, with the hands being the most affected; The time from symptom onset to diagnosis was approximately 11.27 months. Rheumatoid Factor was positive in 83.67% cases, while Anti-CCP showed a positivity of 32% but was performed in fewer patients. The most commonly used drug was methotrexate 31%, followed by leflunomide 17%, and a combination of both 13.67%. Among the biologics, infliximab 6% and tocilizumab 5.33% stood out. Conclusion. In this center, RA primarily affects adult women. It has an oligoarticular clinical presentation, and diagnosis is usually late, with few requests for anti-CCP.

References

Wasserman A. Rheumatoid Arthritis: Common Questions About Diagnosis and Management. Am Fam Physician. 2018;97(7):455–62. https://pubmed.ncbi.nlm.nih.gov/29671563/

Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022;63(2):138–51. https://doi.org/10.1007/s12016-021-08890-1

Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–71. https://doi.org/10.1136/annrheumdis-2019-215920

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584

Díaz Pérez L, Martínez González E, Nerey González W, Morales Nerey MG. Caracterización clínica y epidemiológica de pacientes con Artritis Reumatoide y manifestaciones cardiorrespiratorias. Acta Med Cent. 2022;16(4):644–54. http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S2709-79272022000400644&lng=es&nrm=iso&tlng=es

Cabrera-Villalba S, Román L, Yinde Y, Ojeda A, Duarte M. Características clínicas de pacientes paraguayos con Artritis Reumatoide establecida. Rev Paraguaya Reumatol. 2015;1(2):94–8. https://www.revista.spr.org.py/index.php/spr/article/view/21

Abreu P de. Recomendaciones de la Sociedad Paraguaya de Reumatología sobre el uso de terapias biológicas en la Artritis Reumatoide. Rev Paraguaya Reumatol. 2015;1(1):2–10. https://www.revista.spr.org.py/index.php/spr/article/view/7

Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11):2857. https://doi.org/10.3390/cells10112857

Armas Rodríguez WE, et al. Artritis reumatoide, diagnóstico, evolución y tratamiento. Rev Cuba Reumatol. 2019;21(3). http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1817-59962019000300013&lng=es&nrm=iso&tlng=es

Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2019;27(6):501–7. https://doi.org/10.1159/000493390

Ministerio de Salud Pública y Bienestar Social. Jaikuaami mba´épa umi ojeheróva “enfermedades reumáticas”. 2023. https://www.mspbs.gov.py/portal/28381/jaikuaami-mbaacuteepa-umi-ojeherova-enfermedades-reumaticas.html

Villalba SC, Coronel C, Román L, Valinotti V, Amarilla A, Zarza M, et al. Caracterización clínico epidemiológica de una cohorte de pacientes con Artritis Reumatoide: Datos preliminares. Rev Paraguaya Reumatol. 2024;10(2):55–61. https://doi.org/10.18004/rpr/2024.10.02.55

Garcés Salazar MC, Paredes Cuesta DM, Martínez Gualpa LR. Relación entre hipotiroidismo y artritis reumatoide. Rev Cuba Reumatol. 2019;21(2). http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1817-59962019000200002&lng=es&nrm=iso&tlng=es

Fallon EA, Boring MA, Foster AL, Stowe EW, Lites TD, Odom EL, et al. Prevalence of Diagnosed Arthritis — United States, 2019–2021. MMWR Morb Mortal Wkly Rep. 2023;72(41):1101-1107. https://doi.org/10.15585/mmwr.mm7241a1

Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:34). https://doi.org/10.1186/s41927-019-0080-9

Gomes RKS, De Linhares AC, Lersch LS. Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil. Adv Rheumatol. 2018;58:35). https://doi.org/10.1186/s42358-018-0034-8

Mercado U, Barbosa B. Manifestaciones extraarticulares de artritis reumatoide. Med Int Méxi. 2016;32(6):607–11. https://www.medigraphic.com/pdfs/medintmex/mim-2016/mim166b.pdf

Pramod Gr, Dihingia P, Jha AK, Gadgade A, Agarwal D. Rheumatoid Arthritis Co-relation with Anti-CCP Antibodies with special reference to its Prevalence in Asymptomatic First-Degree Relatives. Mediterr J Rheumatol. 2022;33(1):42–7. https://doi.org/10.31138/mjr.33.1.42

Elsaman A, Radwan A, Dahab MA, Sherif A, Abu EAF. AB0291 Epidemiology and comorbidity of rheumatoid arthritis in upper egypt, a hospital based study. Ann Rheum Dis. 2017;76(Suppl 2):1150. https://doi.org/10.1136/annrheumdis-2017-eular.1440

Gheita TA, Raafat HA, El-Bakry SA, Elsaman A, El-Saadany HM, Hammam N, et al. Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance. Rheumatol Int. 2023;43(4):667–76. https://doi.org/10.1007/s00296-022-05258-2

Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, et al. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis. 2018;21(8):1581–90. https://doi.org/10.1111/1756-185X.13243

Veloz Aranda JA. Asociación de toxicidad hepática en pacientes con artritis reumatoide con el uso de metotrexato y leflunomida en monoterapia y combinado. [Tesis de maestría]. León, Guanajuato, México: Universidad de Guanajuato; 2022. http://repositorio.ugto.mx/handle/20.500.12059/7688